Journals / Neurological sciences and neurophysiology (Online) / 2019 / Cilt: 36 - Sayı: 4

The relationship between homocysteine concentrations and possible polyneuropathy in early stages of Parkinson disease

Pages
223–230
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Peripheral nervous system involvement may be a component even in the early stage of this multi-system disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Recent electrophysiologic and pathologic evidence suggests a relationship between idiopathic Parkinson's disease (IPD) and the peripheral nervous system.
📊
Key Findings & Data:Methods: Forty-five patients with IPD and 32 healthy volunteers were included in the study.
💡
Conclusion & Impact:Peripheral nervous system involvement may be a component even in the early stage of this multi-system disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: Recent electrophysiologic and pathologic evidence suggests a relationship between idiopathic Parkinson's disease (IPD) and the peripheral nervous system. The purpose of this study was to determine whether there was a relationship between homocysteine (Hcy) concentrations and possible polyneuropathy in the early stages of Parkinson disease from an electrophysiologic aspect. Methods: Forty-five patients with IPD and 32 healthy volunteers were included in the study. The clinical staging of disease was performed using the Modified Hoehn & Yahr Staging Scale, and the clinical severity was performed using the Unified Parkinson's Disease Rating Scale. The Neuropathy Impairment Score of the Lower Limbs was used for the clinical evaluation of polyneuropathy. Median, ulnar, tibial, and peroneal motor nerve conduction studies, and median, ulnar, sural sensory nerve conduction studies were performed in all subjects in both groups. Results: A significant difference was determined between the groups because polyneuropathy was detected in 44.4% of patients compared with 3.1% in the control group. Neuropathy Impairment scores were significantly higher in the patient group compared with the control group (p<0.001). Serum Hcy concentrations were also significantly higher in the patient group than in the control group (p<0.001). No significant difference was determined between the Hcy concentrations of patients with or without polyneuropathy. Conclusion: Elevated Hcy concentrations that are considered to be induced by levodopa treatment cannot be the only reason for the development of polyneuropathy in IPD. Peripheral nervous system involvement may be a component even in the early stage of this multi-system disease.

🔖

Cite This Article

Tur, E. K., KENANGİL, G., DOMAÇ, F. M. (2019). The relationship between homocysteine concentrations and possible polyneuropathy in early stages of Parkinson disease. Neurological sciences and neurophysiology (Online), Cilt: 36 - Sayı: 4, 223–230. https://ajindex.com/articles/290585

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Müller T, Renger K, Kuhn W. Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Arch Neurol 2004
  2. [CrossRef] 2. Ceravolo R, Cossu G, Bandettini di Poggio M, et al. Neuropathy and levodopa in Parkinson’s disease: evidence from a multicenter study. Mov Disord 2013
  3. [CrossRef] 3. Nolano M, Provitera V, Lanzillo B, Santoro L. Neuropathy in idiopathic Parkinson disease: an iatrogenic problem? Ann Neurol 2011
  4. [CrossRef] 4. Donadio V, Incensi A, Piccinini C, et al. Skin nerve misfolded α-synuclein in pure autonomic failure and Parkinson disease. Ann Neurol 2016
  5. [CrossRef] 5. Vital A, Lepreux S, Vital C. Peripheral neuropathy and parkinsonism: a large clinical and pathogenic spectrum. J Peripher Nerv Syst 2014
  6. [CrossRef] 6. Doppler K, Ebert S, Uçeyler N, et al. Cutaneous neuropathy in Parkinson’s disease: a window into brain pathology. Acta Neuropathol 2014
  7. [CrossRef] 7. Podgorny PJ, Suchowersky O, Romanchuk KG, Feasby TE. Evidence for small fiber neuropathy in early Parkinson’s disease. Parkinsonism Relat Disord 2016
  8. [CrossRef] 8. Toth C, Breithaupt K, Ge S, et al. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol 2010
  9. [CrossRef] 9. dos Santos EF, Busanello EN, Miglioranza A, et al. Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson’s disease. Metab Brain Dis 2009
  10. [CrossRef] 10. Doherty GH. Homocysteine and Parkinson’s disease: a complex relationship. J Neurol Disord 2013
  11. Rajabally YA, Martey J. Levodopa, vitamins, ageing and the neuropathy of Parkinson’s disease. J Neurol 2013
  12. [CrossRef] 12. Gondim Fde A, de Oliveira GR, Peixoto AA Jr, Horta WG. A case series of peripheral neuropathy in patients with Parkinson’s disease. Ann Neurol 2010
  13. [CrossRef] 13. Rivner MH, Swift TR, Malik K. Influence of age and height on nerve conduction. Muscle Nerve 2001
  14. [CrossRef] 14. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 2010
  15. 2 649-2653. [CrossRef] 15. Bril V. NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. Eur Neurol 1999
  16. [CrossRef] 16. Rajabally YA, Martey J. Neuropathy in Parkinson disease: prevalence an